2017 was a year for the record books at the Patent Trials and Appeal Board (PTAB), which has included newly created standard operating procedures from the PTAB, a landmark en banc ruling from the Court of Appeals for the Federal Circuit impacting amendment practice, and a series of informative decisions from PTAB impacting multiple proceedings … Continue reading this entry
Tags: amendment, aqua, en banc, generic ipr, ipr stats, oil states, pharmaceutical ipr, ptab, sovereign immunity, supreme court, year in review
We have reviewed a sub-group of 111 IPRs filed by generic drug companies against pharmaceutical patents to assess outcomes and trends. While our survey was not intended to capture every IPR filed by a generic drug company, it does cover the most active generic company filers to date (see Fig. 2 below). Examining this particular group … Continue reading this entry
Tags: anda, generic petitioner, ipr, late filer, pharmaceutical ipr, ptab, settlement, statistics, termination
Posted in Practice Insights; PTAB Decisions